The last day of June 2017 saw the Supreme Court of Canada (SCC) quash the controversial Promise Doctrine. The issue at hand in AstraZeneca Canada Inc v Apotex Inc was…
Category: Access to Medicines
in Access to Medicines, Commercialization, Design, Development, IP, Patentability, Patents, Pharmaceutical Drugs, Uncategorized0by Editor
756
What Makes It My Molecule: A Look at Professor Ronald Pearlman’s Genome Editing Work
This past November, Professor Ronald E. Pearlman from York University’s Department of Biology gave a talk [1] at Osgoode Hall Law School to discuss the potential of the innovative CRISPR…
Breaking the Fall Off the Patent Cliff: Can Developing Countries Help Big Pharma?
Expiring patents are expected to contribute billions of dollars towards the loss of revenue of drug manufacturers in the years to come. To save itself from falling off the patent cliff,…
Virotech Patents, Viropiracy, and Viral Sovereignty
INTRODUCTION Access to medicines goes hand in hand with the protection of intellectual property rights. At a time when the United States is undertaking large-scale reforms in both the intellectual…
in Access to Medicines, Human Rights, Human Rights Issues, Innovation, Internet, IP, Social Justice, Tech Transfer, Technology0by Editor
553
The Future of Rights: Intellectual Property, Economic Inequality and the ‘Digital Divide’
A quarter century since he helped to create it, the man widely regarded as the creator of the World Wide Web, Tim Berners-Lee, has renewed calls for a Digital Bill…
in Access to Medicines, Blogs, Canada, Cross Border Issues, IP, IP Reform, Jurisdiction, Patents, Pharmaceutical Drugs, Regulatory Policy, Trademarks0by Editor
301
Canada’s IP Laws and the Comprehensive Economic and Trade Agreement (CETA): Canada Got the Short End of the Proverbial Stick
The outline of CETA has arrived – but its full text is still in transit. On what we know of the intellectual property aspects of CETA, Canada got the short…